RVPHMEDIUM SIGNALFINANCIAL10-K

RVPH executed a 1:20 reverse stock split while reducing operating losses and cutting R&D expenses by nearly half year-over-year.

The reverse stock split from 46.7 million to 12.8 million shares suggests the company was addressing potential delisting concerns or attempting to improve share price perception. The substantial reduction in R&D spending alongside improved operating metrics indicates either cost-cutting measures or completion of major trial phases, which could signal either financial pressure or a strategic pivot in drug development priorities.

Comparing 2026-03-30 vs 2025-04-03View on EDGAR →
FINANCIAL ANALYSIS

RVPH demonstrated improved financial performance with operating losses narrowing by over 30% to $20.2M and net losses similarly reduced to $19.9M. The company meaningfully reduced R&D expenses to $11.7M while cutting total liabilities in half to $7.3M, suggesting aggressive cost management. Operating cash flow improved modestly to -$24.6M, indicating the company is burning through cash at a slower rate while maintaining its drug development operations.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
-50.5%
$14.7M→$7.3M

Liabilities reduced 50.5% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-50.2%
$14.6M→$7.3M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-48.9%
$22.9M→$11.7M

R&D spending cut 48.9% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+34.4%
-$30.8M→-$20.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+33.6%
-$29.9M→-$19.9M

Net income grew 33.6% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+26.7%
-$33.5M→-$24.6M

Operating cash flow grew 26.7% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-04-03
ADDED
As of March 27, 2026 the number of outstanding shares of the registrant s common stock, par value $0.0001 per share, was 12,810,377 .
Forward-looking statements are not guarantees of performance.
Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208 (Figure 1).
Recent Developments Reverse Stock Split At our annual stockholders meeting held on December 18, 2025, our stockholders adopted and approved an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding shares of common stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-twenty (1:20), at any time prior to December 31, 2026, with such ratio to be determined by our Board of Directors ( Board ) in its discretion.
On March 4, 2026, we filed an amendment to our Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to effect a reverse stock split of our issued and outstanding common stock at a ratio of one-for-twenty (1:20) (the Reverse Stock Split ).
+7 more — sign up free →
REMOVED
Employer Identification No.) incorporation or organization) 10080 N.
As of March 14, 2025 the number of outstanding shares of the registrant s common stock, par value $0.0001 per share, was 46,739,949 .
In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
Our pipeline currently has two drug candidates, brilaroxazine (RP5063) and RP1208.
On October 30, 2023, we announced positive topline results from our Phase 3 RECOVER 1 trial (the RECOVER-1 Trial ), which is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of brilaroxazine in approximately 400 patients with acute schizophrenia compared to placebo.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →